How did ImmunityBio (NASDAQ:IBRX) perform in 2025?

ImmunityBio reported impressive financial results for 2025, with net product revenue from its lead asset, ANKTIVA®, reaching $113 million—a 700% increase compared to 2024. This growth was driven by strong adoption in the non-muscle invasive bladder cancer (NMIBC) market, and a 750% surge in unit sales volume.

What fueled the explosive growth of ImmunityBio's ANKTIVA® in 2025?

The growth of ANKTIVA® was driven by broad physician uptake and its successful integration into oncology treatment pathways, particularly for NMIBC. The company also saw a surge in unit sales volume, which contributed to the 700% revenue increase for the year.

How did ImmunityBio perform in Q4 2025?

ImmunityBio posted a 20% quarter-over-quarter revenue increase in Q4, continuing its strong growth trajectory. This indicates the company’s momentum in scaling its commercial operations as it expands ANKTIVA®’s presence in the market.

What regulatory milestones did ImmunityBio achieve in 2025?

ImmunityBio achieved a major regulatory milestone by securing its first approval for ANKTIVA® in a new indication: as a combination therapy with checkpoint inhibitors for lung cancer treatment. This expands the drug's addressable market significantly beyond its use in urology, tapping into the high-volume thoracic oncology space.

How does ImmunityBio’s global footprint look after 2025?

As of 2025, ImmunityBio has expanded its global footprint to 33 countries across four jurisdictions. This global presence supports the company’s growing commercialization efforts and lays the foundation for expanding ANKTIVA®'s reach in multiple therapeutic areas.

Health

Image for illustrative purposes only. Not a real photo.

ImmunityBio surges as ANKTIVA revenue jumps 700% in breakthrough 2025

Written by Mahathir BayenaPublished Feb 23, 2026, 12:00 AMLast Updated Jul 6, 2026, 10:45 AM

ImmunityBio (NASDAQ:IBRX), the California-based immunotherapy leader, reported explosive 2025 financial results on Monday, signaling its successful transition into a high-growth commercial powerhouse.

The company’s lead asset, ANKTIVA®, generated $113 million in net product revenue for the full year—a staggering 700% increase compared to 2024—driven by rapid adoption in the non-muscle invasive bladder cancer (NMIBC) market.

The commercial momentum was fueled by a 750% surge in unit sales volume, reflecting broad physician uptake and successful integration into oncology treatment pathways.

ImmunityBio maintained a strong growth trajectory through the end of the year, posting a 20% quarter-over-quarter revenue increase in the fourth quarter.

Beyond the balance sheet, 2025 marked a pivotal regulatory expansion for the company.

ImmunityBio now boasts a global footprint spanning 33 countries across four jurisdictions.

Most notably, the company secured its first regulatory approval for ANKTIVA in a new indication: a combination therapy with checkpoint inhibitors for the treatment of lung cancer.

This milestone significantly expands the drug's addressable market beyond urology and into the high-volume thoracic oncology space.

ImmunityBio surges as ANKTIVA revenue jumps 700% in breakthrough 2025

Perguntas frequentes

Ativos relacionados a notícia